BREAKING NEWS: First-in-the-World Ivermectin, Mebendazole, and Fenbendazole Protocol in Cancer Has Been Peer-Reviewed and Published on Sep. 19, 2024!

By Medeea Greere,

• • •

Spearheaded by lead authors Ilyes Baghli and Pierrick Martinez, along with FLCCC’s Dr. Paul Marik, the publication of the world’s first peer-reviewed protocol involving Ivermectin, Mebendazole, and Fenbendazole opens the door to transformative possibilities. These repurposed drugs, once limited to treating parasitic infections, are showing undeniable potential in the battle against cancer. The publication of this research serves as a beacon of hope for patients, families, and healthcare professionals everywhere.

The Future of Cancer Treatment Starts Now. For decades, cancer patients and their families have waited for breakthroughs in treatment. That moment is now. The publication of this protocol does more than just present new scientific findings. It lays a roadmap for a future where cancer treatment is not just about managing symptoms or prolonging life for a few more months—it’s about potentially achieving cures, faster recoveries, and better outcomes.

In recent years, there has been growing interest in repurposed drugs—medications originally developed for other diseases that are found to have beneficial effects in treating different conditions. This protocol is a product of that movement. By using Ivermectin, Mebendazole, and Fenbendazole—three drugs previously known for treating parasites—the research presents a new way forward in cancer care. It is a significant departure from conventional oncology that, until now, has focused heavily on chemotherapy, radiation, and immunotherapy.

A Revolutionary Step Forward. The research conducted by Ilyes Baghli, Pierrick Martinez, and their team is nothing short of revolutionary. These scientists and doctors didn’t just stop at observing promising results—they painstakingly pursued rigorous peer review to ensure their findings would hold up under the scrutiny of the medical community. Peer review is the gold standard of scientific validation, meaning that the published results have been critically examined and deemed reliable by experts in the field.

The Role of Repurposed Drugs in Cancer Treatment. Repurposing drugs is not a new concept, but the focus on Ivermectin, Mebendazole, and Fenbendazole for cancer treatment is relatively recent. These drugs, primarily known for their ability to combat parasites, have shown promising anti-cancer properties. Ivermectin has been the subject of numerous studies for its anti-inflammatory, antiviral, and now, anticancer effects. Similarly, Mebendazole and Fenbendazole are antiparasitic drugs that have been shown to disrupt cancer cell growth and proliferation.

The potential of these drugs lies in their ability to inhibit the formation of microtubules, which are essential structures within cancer cells. By targeting these, the drugs can slow or stop the uncontrolled cell division characteristic of cancer. Furthermore, these drugs appear to work synergistically, meaning their combined effects are greater than their individual impacts, creating a more potent anti-cancer weapon.

Gratitude to the Innovators. While many celebrate this groundbreaking development, it’s important to recognize the efforts of the scientists and doctors who made it possible. Lead authors Ilyes Baghli and Pierrick Martinez deserve immense credit for their visionary approach and dedication. Their innovative thinking and rigorous research have made it possible for a new protocol to emerge.

Special thanks also go to Dr. Paul Marik, a leading figure in the FLCCC (Front Line COVID-19 Critical Care) Alliance, whose work on repurposed drugs has paved the way for this revolutionary cancer treatment. It’s crucial to recognize the contributions of each co-author, whose tireless efforts have given hope to cancer patients around the world.

Incredible Successes Already Being Seen. Many may wonder: does this new protocol really work? The answer is an overwhelming yes. Thousands of cancer patients have already experienced remarkable improvements thanks to this new approach. High doses of Ivermectin, Mebendazole, and Fenbendazole are producing positive outcomes, and these results are no longer anecdotal—they’re being documented in scientific research.

Patients who had exhausted all other options, who were told they had little time left, are now experiencing regression of their tumors and remission. What makes these successes even more incredible is that these drugs are widely available and affordable, unlike the exorbitantly expensive chemotherapy or immunotherapy treatments that can often bankrupt families.

Why Are These Drugs Effective? The science behind why these drugs are effective is becoming clearer. Ivermectin, for example, has been found to disrupt the signaling pathways that cancer cells rely on to grow and spread.

Mebendazole and Fenbendazole work by targeting the microtubules in cancer cells, preventing them from dividing and multiplying. What’s even more exciting is that these drugs have minimal side effects, making them a much more tolerable option compared to the debilitating effects of traditional cancer treatments.

Moreover, these drugs have the potential to target a wide range of cancers, meaning their application is not limited to a single cancer type. From breast cancer to melanoma to lung cancer, the protocol is showing promise across the board. This broad applicability is one of the most exciting aspects of the research.

Mainstream Oncology’s Collapse After COVID-19. While this protocol signals hope for the future, it also exposes the failures of mainstream oncology. In the aftermath of the COVID-19 pandemic, traditional cancer treatment has faced a massive crisis. The rollout of mRNA vaccines—which many oncologists recommended to their patients—has proven disastrous for cancer patients.

Contaminated mRNA Vaccines: A Catastrophic Impact on Cancer Patients. Mainstream oncologists have been administering contaminated COVID-19 mRNA vaccines to their patients, with devastating consequences. These vaccines, intended to prevent viral infections, have caused a surge in adverse effects among cancer patients. The very doctors entrusted with their patients’ lives—those who took an oath to “do no harm”—have failed them.

Many oncologists, following the herd and disregarding the warnings, have even taken these vaccines themselves, and the results have been tragic. Cases of mRNA-induced cardiac arrests, blood clots, and even “Turbo Cancer”—aggressive cancers that spread rapidly after vaccination—have been reported. These oncologists, who should have known better, now find themselves victims of their own negligence.

Oncologists Have Abandoned Their Oath. The very foundation of medicine, the Hippocratic Oath, has been discarded by many oncologists in favor of compliance with the pharmaceutical industry’s push for the mRNA vaccine. These doctors buried their heads in the sand, ignoring the growing evidence that these vaccines were not only ineffective for cancer patients but also harmful. By doing so, they failed to uphold their responsibilities and the trust placed in them by their patients.

The Path Forward: A New Era in Cancer Treatment. While many oncologists have lost their way, there are those in the medical community who are blazing a new trail. These forward-thinking doctors are rejecting the flawed narrative and embracing repurposed drugs as the future of cancer treatment. This Ivermectin, Mebendazole, and Fenbendazole protocol represents the cutting edge of this new path.

The publication of this peer-reviewed paper lays the groundwork for a paradigm shift in how we approach cancer treatment. It opens the door to personalized, more effective therapies that could change the way we fight cancer. With more research and clinical trials, we may soon see these repurposed drugs becoming a standard part of cancer treatment protocols worldwide.

Looking Toward the Future. The next steps involve rigorous clinical testing and further research, but the potential is already clear. As more doctors become aware of this protocol and patients continue to benefit from its effects, the future looks bright. The hope is that this new approach will not only save lives but also transform the medical community from one that often relies too heavily on the pharmaceutical industry’s influence to one that prioritizes patient health and well-being above all else.

A New Hope for Cancer Patients. The publication of this protocol marks a turning point in the fight against cancer. Ivermectin, Mebendazole, and Fenbendazole have the potential to change the lives of millions of cancer patients worldwide. This breakthrough comes at a time when mainstream oncology has faltered, exposing its failures in the wake of the COVID-19 pandemic.

But hope remains. Thanks to the visionary work of researchers like Ilyes Baghli, Pierrick Martinez, and Dr. Paul Marik, we are entering a new era of cancer treatment. A future where cancer is not a death sentence, but a condition that can be effectively managed—and even cured—using affordable, accessible, and repurposed drugs.

The future of cancer treatment is here. And it starts now.

Source: https://threadreaderapp.com

Your Tax Free Donations Are Appreciated and Help Fund our Volunteer Website

Disclaimer: We at Prepare for Change (PFC) bring you information that is not offered by the mainstream news, and therefore may seem controversial. The opinions, views, statements, and/or information we present are not necessarily promoted, endorsed, espoused, or agreed to by Prepare for Change, its leadership Council, members, those who work with PFC, or those who read its content. However, they are hopefully provocative. Please use discernment! Use logical thinking, your own intuition and your own connection with Source, Spirit and Natural Laws to help you determine what is true and what is not. By sharing information and seeding dialogue, it is our goal to raise consciousness and awareness of higher truths to free us from enslavement of the matrix in this material realm.